The US Food and Drug Administration (FDA) has approved daxibotulinumtoxinA-lanm injection (Daxxify) for the temporary improvement in the appearance of moderate to severe glabellar lines (frown lines) ...
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, responds to the public disclosure of ...
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced it has resubmitted its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback